NR2F6‑AIM has advanced ACT for solid tumors beyond the current state of the art in several key dimensions at the preclinical level (see Humer, D., Klepsch, V., Rieder, D. et al. NR2F6 deletion revives CAR‑T cell function and induces antigen‑agnostic immune memory in solid tumors. Nat Commun (2026).
https://doi.org/10.1038/s41467-026-69796-0(se abrirá en una nueva ventana) First, it establishes, for the first time, an intracellular checkpoint inhibition strategy that specifically targets NR2F6 in T cells to reprogram their effector function and to induce a secondary host antitumor response, in which CAR‑mediated cytotoxicity not only kills tumor cells but also promotes endogenous T cell priming in an in situ “kill‑and‑vaccinate” manner. This approach combines the potency of NR2F6 checkpoint blockade with a potentially more favorable safety profile based on a secondary, polyclonal immune response by the patient, thereby reducing the theoretical risk of immune escape driven by antigen loss or clonal restriction.
Second, in principle, the key preclinical results suggest that NR2F6‑modified ACT could be implemented by non‑genomic, siRNA‑based technologies as a point‑of‑care procedure using PBMC‑derived T cells, thereby significantly improving CAR‑T manufacturing compared with conventional TIL and CAR‑T therapies. This non‑viral manufacturing concept might reduce costs, increase patient access and make personalized ACT more compatible with routine clinical workflows in oncology centers, and the optimized protocol together with preclinical data offers an initial blueprint for later translation into a GMP setting and for designing potential first‑in‑human trials in solid tumors such as MM. The central future idea is to use a non‑viral, “time‑boxed” siRNA transfection of PBMC‑derived T cells to transiently silence NR2F6, followed by rapid reinfusion, enabling a one‑day, in‑hospital ACT preparation that avoids lengthy ex vivo expansion and permanent genomic modification while still inducing potent antitumor immunity in a hostile TIME.
Taken together, the project positions NR2F6 as a promising and potentially clinically actionable immune checkpoint and platform target in solid tumors with NR2F6‑driven immune suppression, thereby opening new research and innovation avenues in solid tumor immunotherapy. The consolidated IP portfolio and refined commercial strategy provide a strong basis to develop, own and exploit NR2F6‑based ACT innovations in Europe, with potential benefits for patients, healthcare systems and the biotech sector, and together these achievements deliver a technically validated, IP‑protected and commercially assessed ACT concept that can now be further advanced through dedicated, future clinical development programs.
Figure legend: NR2F6 AIM explored a new way to make personalized immunotherapy more powerful for patients with solid cancers such as melanoma. By switching off the intracellular checkpoint NR2F6 in engineered CAR T cells (upper left), the project showed in preclinical models that these cells not only kill tumors more efficiently but can also “vaccinate” the host immune system to recognize the cancer more broadly by triggering a secondary and polyclonal immune memory beyond the initially targeted CAR antigen (such as MSLN). This work lays the scientific and strategic foundation for future development of faster, safer, more effective and more accessible cell therapies.
